MarketCap
Facebook
X
TelegramQuartalsbericht 2022-Q2
hinzugefügt 09.08.2022
Radius Health Betriebsaufwand 2011-2026 | RDUS
Betriebsaufwand Jährlich Radius Health
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 304 M | 269 M | 295 M | 270 M | 185 M | 99.1 M | 59.4 M | 67.4 M | 64.4 M | 41.5 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 304 M | 41.5 M | 165 M |
Betriebsaufwand anderer Aktien in der Arzneimittelhersteller
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
71.8 M | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
38.9 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
213 M | - | - | $ 754 M | USA |
 |
Cronos Group
CRON
|
154 M | $ 2.69 | 1.32 % | $ 1.42 B |  Canada |
 |
Canopy Growth Corporation
CGC
|
197 M | $ 1.25 | -3.02 % | $ 134 M | Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
40.3 M | - | 7.5 % | $ 6.35 M | USA |
 |
Agile Therapeutics
AGRX
|
30.5 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
512 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
44.6 M | - | - | $ 50.1 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
213 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
106 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Eagle Pharmaceuticals
EGRX
|
113 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
763 M | - | - | $ 28.9 M |  Irlanda |
 |
OrganiGram Holdings
OGI
|
41.4 M | $ 1.74 | 0.29 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
368 M | $ 4.17 | -1.07 % | $ 549 M | USA |
 |
Emergent BioSolutions
EBS
|
558 M | $ 12.94 | -3.14 % | $ 663 M | USA |
 |
Evoke Pharma
EVOK
|
12.6 M | - | - | $ 36.6 M | USA |
 |
Athenex
ATNX
|
96.7 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
196 M | $ 21.52 | 0.19 % | $ 2.05 B |  France |
 |
Sundial Growers
SNDL
|
102 K | $ 1.65 | 0.3 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
9.18 M | $ 3.65 | -3.44 % | $ 4.53 M | USA |
 |
Evolus
EOLS
|
107 M | $ 5.61 | -2.35 % | $ 348 M | USA |
 |
Harrow Health
HROW
|
90.1 M | $ 47.21 | -7.51 % | $ 1.54 B | USA |
 |
China Pharma Holdings
CPHI
|
2.6 M | $ 1.29 | -4.79 % | $ 22.5 M |  China |
 |
Tilray
TLRY
|
1.52 B | $ 9.15 | 0.26 % | $ 5.65 B | Canada |
 |
Jupiter Wellness
JUPW
|
39.6 M | - | - | $ 33.6 M | USA |
 |
Bausch Health Companies
BHC
|
4.96 B | $ 7.47 | -3.93 % | $ 2.73 B | Canada |
 |
Lannett Company
LCI
|
209 M | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
35.2 M | $ 4.78 | -1.04 % | $ 67.2 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
55.6 M | - | - | $ 193 M | Canada |
 |
Veru
VERU
|
44 M | $ 2.35 | 1.73 % | $ 317 M | USA |
 |
Aurora Cannabis
ACB
|
183 M | $ 4.25 | -0.47 % | $ 86.3 M | Canada |
 |
Pacira BioSciences
PCRX
|
279 M | $ 23.67 | -9.03 % | $ 1.09 B | USA |
 |
PetIQ
PETQ
|
138 M | - | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
1.43 B | $ 14.99 | 1.94 % | $ 2.06 B | USA |
 |
ProPhase Labs
PRPH
|
47.1 M | - | - | $ 5.07 M | USA |
 |
Recro Pharma
REPH
|
22.5 M | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
28.9 M | $ 1.08 | -0.46 % | $ 4.66 M | USA |
 |
Rockwell Medical
RMTI
|
31.1 M | $ 0.94 | -3.6 % | $ 21.9 M | USA |
 |
Relmada Therapeutics
RLMD
|
104 M | $ 4.27 | -3.61 % | $ 129 M | USA |
 |
OptiNose
OPTN
|
129 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
133 M | $ 9.12 | -2.04 % | $ 648 M | USA |
 |
PLx Pharma
PLXP
|
44.2 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
130 M | $ 5.25 | -1.22 % | $ 214 M | USA |
 |
SCYNEXIS
SCYX
|
67.5 M | $ 0.67 | 0.42 % | $ 32.1 M | USA |
 |
Tricida
TCDA
|
153 M | - | - | $ 3.25 M | USA |
 |
TherapeuticsMD
TXMD
|
9.82 M | $ 2.09 | 1.46 % | $ 21.8 M | USA |
 |
Viatris
VTRS
|
4.88 B | $ 12.74 | 1.07 % | $ 15.4 B | USA |
 |
Zomedica Corp.
ZOM
|
14.1 M | - | -0.21 % | $ 98 M | USA |